ClinicalTrials.gg
RecruitingNCT07439653Updated Sep 28, 2026

A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma

A Phase 1/2 interventional study of TORL-5-700 and TORL-5-700 at MTD/RP2D in Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma, sponsored by TORL Biotherapeutics, LLC. Recruiting at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by TORL Biotherapeutics, LLC · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.
Updated Sep 28, 20263 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
155
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 399 studies in Lymphoma, B-Cell with a site in United States — 91 open to participants now, 157 under way, 12 of them phase 3. Lymphoma, B-Cell · United States.

Planned enrollment
52nd of 381
155 · median 37
Started
2026
with 20 others
Phase 1/2
75 of 399
20 open now
Primary completion
2029-03
later than 122 of 156 live
Registered
384th of 399
by date

Among the 399 studies in Lymphoma, B-Cell with a site in United States, this one is the 52nd largest by planned enrollment of the 381 interventional ones that give a count, is one of 21 that started in 2026, is one of 75 in phase 1/2, reaches primary completion later than 122 of the 156 other live ones, and was the 384th registered.

Lymphoma, B-Cell

889 studies on the registry are indexed under Lymphoma, B-Cell; 289 are open to participants now.

Browse Lymphoma, B-Cell studies →

Open to participants now

91 of the 399 studies in Lymphoma, B-Cell with a site in United States are open now. Recruiting first, the newest first:

85 more — sign in →

All 91 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 209 Lymphoma, B-Cell studies recruiting now, 128 (61%) set no upper age limit and 61 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 399 studies in Lymphoma, B-Cell with a site in United States, or all of them as a file.
02

Study summary

A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL

03

Conditions studied

  • Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed B-NHL, including but not limited to de novo DLBCL; FL, Grades 1 to 3A; MCL; transformed lymphoma (tFL, RT) and FL Grade 3B; MZL and MALT.
  • (ECOG) performance status less than or equal to 2.
  • At least 1 per Lugano criteria.
  • Tumor tissue is available.
  • Adequate organ function

Exclusion criteria

Exclusion Criteria:

  • T-cell lymphoma
  • CLL or SL
  • Burkitt lymphoma and high-grade B-cell lymphoma
  • CNS involvement
  • Peripheral neuropathy > Grade 2
  • Uncontrolled medical conditions
  • Viral infections
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
155 participants (estimated)

Study arms

  • Experimental
    Part 1: Monotherapy Dose Escalation

    TORL-5-700 Administered once every three weeks

    Drug: TORL-5-700

  • Experimental
    Part 2: Monotherapy Expansion

    TORL-5-700 at MTD/RP2D Administered once every three weeks

    Drug: TORL-5-700 at MTD/RP2D

  • Experimental
    Part 3: Combination Evaluation

    TORL-5-700 at MTD/RP2D Administered once every three weeks in combination with another agent

    Drug: TORL-5-700 at MTD/RP2D in combination with another agent

Interventions

  • DrugTORL-5-700

    Part 1: Monotherapy Dose Escalation - TORL-5-700 Administered once every three weeks

  • DrugTORL-5-700 at MTD/RP2D

    Part 2: Monotherapy Expansion - TORL-5-700 at Maximum tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) Administered once every three weeks

  • DrugTORL-5-700 at MTD/RP2D in combination with another agent

    Part 3: Combination Evaluation - TORL-5-700 at MTD/RP2D administered every three weeks in combination with another agent

06

What researchers measure

Primary outcomes

  1. Evaluate the safety of TORL-5-700 as a monotherapy

    Assessment of adverse events according to NCI-CTCAE Version 5.0

    Time frame: though study completion, an average of 2.5 years

  2. Assess the antitumor activity of TORL-5-700 as monotherapy

    Assess the antitumor activity of TORL-5-700 using Cheson (2014) disease grading criteria

    Time frame: though study completion, an average of 2.5 years

  3. Evaluate the safety of TORL-5-700 in combination with other agents

    Assessment of adverse events according to NCI-CTCAE Version 5.0

    Time frame: though study completion, an average of 2.5 years

  4. Determine the Maximum Tolerated Dose (MTD)

    Determine the MTD by assessing Protocol defined Dose Limiting Toxicities (DLT)

    Time frame: 21 days from the start of treatment

  5. Determine the Recommended Phase 2 Dose (RP2D)

    Determine the RP2D by assessing Protocol defined Dose Limiting Toxicities

    Time frame: 21 days from the start of treatment

Secondary outcomes

  1. Maximum Serum Concentration of TORL-5-700 (Cmax)

    Pk assessment

    Time frame: though end of study treatment, an average of 5 months

  2. Maximum Serum Concentration of TORL-5-700 (Cmax) in combination with other agents

    Pk assessment

    Time frame: though end of study treatment, an average of 5 months

  3. Terminal Half-life (t1/2) of Serum TORL-5-700

    Pk assessment

    Time frame: though end of study treatment, an average of 5 months

  4. Terminal Half-life (t1/2) of Serum TORL-5-700 in combination with other agents

    Pk assessment

    Time frame: though end of study treatment, an average of 5 months

  5. Area under the Serum Concentration -Time curve for TORL-5-700 from the time of dosing to the last measurable concentration

    Pk assessment

    Time frame: though end of study treatment, an average of 5 months

  6. Area under the Serum Concentration -Time curve for TORL-5-700 from the time of dosing to the last measurable concentration in combination with other agents

    Pk assessment

    Time frame: though end of study treatment, an average of 5 months

  7. Clearance (CL) of TORL-5-700

    Pk assessment

    Time frame: though end of study treatment, an average of 5 months

  8. Clearance (CL) of TORL-5-700 in combination with other agents

    Pk assessment

    Time frame: though end of study treatment, an average of 5 months

  9. Volume of distribution of TORL-5-700

    PK assessment

    Time frame: though end of study treatment, an average of 5 months

  10. Volume of distribution of TORL-5-700 in combination with other agents

    PK assessment

    Time frame: though end of study treatment, an average of 5 months

  11. Immunogenicity of TORL-5-700

    Immunogenicity will be measured by incidence of treatment emergent ADAs

    Time frame: though end of study treatment, an average of 5 months

  12. Immunogenicity of TORL-5-700 in combination with other agents

    Immunogenicity will be measured by incidence of treatment emergent ADAs

    Time frame: though end of study treatment, an average of 5 months

  13. Assess the preliminary antitumor activity of TORL-5-700 in combination with other agents

    Assess the antitumor activity of TORL-5-700 in combination with other agents using Cheson (2014) disease grading criteria

    Time frame: though study completion, an average of 2.5 years

07

Study locations

9 of 9 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Mar 2029, 36 months after the start.

Of 94 phase 1/2 interventional studies under Lymphoma, B-Cell, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 55 and three quarters within 96. This study's planned 36 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2026
First posted
Feb 27, 2026
StartActual
Mar 31, 2026
Primary completionEst.
Mar 31, 2029
CompletionEst.
Sep 30, 2029
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added
Show 3 added (3 United States)
  • Cancer and Blood Specialty Clinic, Los Alamitos · Los Alamitos, United States
  • University of California Miami, Sylvester Comprehensive Cancer Center · Miami, United States
  • Cancer Center of Kansas, Wichita · Wichita, United States
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    3 sites added
    Show 3 added (3 United States)
    • Cancer and Blood Specialty Clinic, Los Alamitos · Los Alamitos, United States
    • University of California Miami, Sylvester Comprehensive Cancer Center · Miami, United States
    • Cancer Center of Kansas, Wichita · Wichita, United States

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07439653
Lead sponsor
TORL Biotherapeutics, LLC
Responsible party
Sponsor
First posted
Feb 27, 2026
Start date
Mar 31, 2026
Primary completion
Mar 31, 2029 (estimated)
Completion
Sep 30, 2029 (estimated)
Last update
Sep 28, 2026

Study contacts

Eric Park, M.D.
Contact
eric.park@torlbio.com
(310) 598-5969

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion